Nucleoside derivatives for treating Hepatitis C virus infection

• US 7,432,248 B2
• Filed: 07/24/2006
• Issued: 10/07/2008
• Est. Priority Date: 09/30/2002
• Status: Expired due to Fees

• Current Assignee: Smithkline Beecham Corporation (Smithkline Beecham PLC)
• Original Assignee: Genelabs Technologies, Inc. (GlaxoSmithKline PLC)
• Inventors: Roberts, Christopher D., Dyatkina, Natalia B., Keicher, Jesse
• Primary Examiner(s): Lewis; Patrick T.
• Assistant Examiner(s): Crane; Lawrence E.
• Application Number:
  US11/492,558
• Publication Number:
  US 20060258613A1
• Time in Patent Office: 806 Days
• Field of Search: 536/27.2, 514/45
• US Class Current: 514/43
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: C07H 19/00 Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
• CPC Class Codes: C07H 19/167 with ribosyl as the saccharide radical

Abstract

Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows:

wherein W, W¹, W², Y, R¹, Z, Y′ and R are as defined herein.

Claims

1. A compound of Formula I below:

2. A compound of claim 1, wherein one of W¹ and W² is an acyl group selected from the group consisting of acetyl, trimethylacetyl, and acyl groups derived from amino acids.

3. A compound of claim 1, wherein, Z is selected from the group consisting of formyl, nitro, acetylenyl and substituted acetylenyl of the formula —

C≡

C—

R⁴ where R⁴ is as defined above.

4. A compound of claim 3 wherein, Z is selected from formyl, nitro, and —

C≡

C—

R⁴ and R¹ is selected from phenyl, and —

Si(CH₃)₃.

5. A pharmaceutical composition comprising a pharmaceutically acceptable diluent and a therapeutically effective amount of a compound of claim 1.